Testing ZG006 and ZG005 for lung and neuroendocrine cancers
Part of Cancer, Lungs & breathing clinical trials.
This trial tests two new drugs, ZG006 and ZG005, for people with advanced small cell lung cancer or neuroendocrine carcinoma. The goal is to see if these drugs can shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have a confirmed diagnosis of advanced small cell lung cancer or neuroendocrine carcinoma.
- You must be able to take care of yourself (light work or better) — this is called an ECOG score of 0 or 1.
- Your doctor must expect you to live more than 3 months.
- You must be willing to sign a consent form after understanding the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new drug called ZG006 for people with advanced small cell lung cancer or neuroendocrine carcinoma. The study has two parts: first finding the right dose, then testing it in more people with neuroendocrine carcinoma.
This trial tests a new drug called ZG006 for people with advanced small cell lung cancer or a type of neuroendocrine cancer. It aims to find the best dose and see if it helps shrink tumors.
This trial tests a new drug, ZG006, that targets a protein called DLL3 found on some cancer cells. It may be an option for people with small cell lung cancer or neuroendocrine carcinoma who have run out of standard treatments.
This trial tests a new drug called ZG006 for people with small cell lung cancer that has not responded to or can no longer tolerate standard treatments. The goal is to find the best dose and see if it can help shrink or control the cancer.
This study compares a new drug called ZG006 against standard chemotherapy for people with small cell lung cancer that has come back after prior treatment. The goal is to see if ZG006 works better or has fewer side effects.
This study tests whether a new drug called ZG006 works better than standard chemotherapy for advanced neuroendocrine carcinoma (a rare cancer that starts in hormone-producing cells). You'll be randomly assigned to receive either ZG006 or a chemotherapy your doctor chooses.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.